tiprankstipranks
Trending News
More News >

Sandoz Invests $440 Million in Slovenian Biosimilars Hub

Story Highlights
Sandoz Invests $440 Million in Slovenian Biosimilars Hub

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Sandoz Group Ltd ( (CH:SDZ) ).

Sandoz has announced a USD 440 million investment in a new biosimilars production center in Brnik, Slovenia, as part of its strategy to capitalize on the USD 222 billion biosimilar patent-expiry market opportunity over the next decade. This investment is part of a larger USD 1.1 billion commitment in Slovenia, aimed at creating a leading European biosimilar hub. The new facility will enhance Sandoz’s manufacturing capabilities, ensuring the production of high-quality, affordable biosimilars and strengthening its position as a global leader in the biosimilars market. The investment highlights Slovenia’s strategic value, with its skilled workforce and robust infrastructure, and underscores Sandoz’s dedication to expanding patient access to biologic medicines.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF45.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

More about Sandoz Group Ltd

Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. The company has a rich history of pharmaceutical breakthroughs and is committed to pioneering patient access to essential medicines. With a diverse portfolio of approximately 1,300 products, Sandoz addresses a wide range of diseases and generates significant healthcare savings worldwide.

Average Trading Volume: 1,232,520

Current Market Cap: CHF19.07B

For an in-depth examination of SDZ stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1